A similar combination of everolimus, an mTOR inhibitor, and panobinostat, a pan-HDAC inhibitor, was evaluated in a phase I clinical trial in patients with lymphoma, including Hodgkin lymphoma [30]. Here, MTOR is linked to Hodgkins lymphoma.